# OnCo record alaw-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/alaw-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "alaw-therapeutics" ;
  schema:name "Alaw Therapeutics"@en ;
  schema:description "Alaw Therapeutics makes pills that block CDK2 and CDK4, enzymes that drive cancer cell division, and designs them to reach the brain. Its CDK2 blocker AL-605 began its first human trial in 2026 in breast, ovarian and other cancers with extra copies of the cyclin E1 gene."@en ;
  schema:url <https://onco.cc/companies/alaw-therapeutics/>, <https://www.alawtx.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.alawtx.com/>, <https://www.alawtx.com/about>, <https://www.alawtx.com/news1/alaw-therapeutics-announces-two-major-pipeline-milestones-advancing-brain-penetrant-cdk-oncology-programs> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/tnbc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/cdk46-inhibitor/> ;
  onco:targets <https://onco.cc/targets/cdk2/>, <https://onco.cc/targets/cdk4-6/>, <https://onco.cc/targets/ccne1/>, <https://onco.cc/targets/egfr/> .